Norway's pharmaceutical intermediate industry operates under stringent environmental regulations and extreme climatic conditions. The reliance on Liquid cooling systems is paramount to maintaining the integrity of volatile chemical reactions during the winter months, where ambient temperature fluctuations can affect reactor efficiency.
In the production of high-purity medicinal precursors, the adoption of Perfluoropolyether oil has become essential. These fluids provide the necessary non-reactive environment, preventing contamination in synthesis processes that are critical for Norway's high-export pharmaceutical standards.
Current industrial clusters in Norway are increasingly shifting toward sustainable, low-volatility heat transfer fluid options. This transition is driven by the need to reduce VOC emissions and improve the energy efficiency of large-scale heating and cooling cycles used in intermediate synthesis.
